Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026

Parkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism—neurological disorders that lead to movement problems. While the exact cause of Parkinson’s disease is unknown, it may include a number of factors such as aging, environmental factors/exposures, and genetic predispositions.

Current treatments centre on the management of dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the Parkinson’s market for the past half century. These therapies provide the best relief of symptoms at a low annual cost of therapy (ACOT), with Sinemet (carbidopa/levodopa) and Madopar (benserazide/levodopa) being the two most popular branded drugs.

GlobalData estimates that drug sales for PD in 2016 were approximately $3.1B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $8.8B at a CAGR of 11.1%. This growth will be driven by the launch of thirteen late-stage pipeline products. The two highest selling drugs are expected to be Roche/Prothena’s PRX-002and Acorda’s CVT-301, which both address some of the unmet needs in the market.

Key Questions Answered

What are the key PD treatments in 2016?

When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?

Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2016 to 2026.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase III development are profiled.

Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Teva

Roche

Prothena

Acorda Therapeutics

Voyager Therapeutics

Impax Pharmaceuticals

UCB

AbbVie

Novartis

Orion Pharmaceuticals

Intec Pharma

NeuroDerm

Adamas Therapeutics

Acadia

Sunovion

Roche

MSD

GSK

Britannia Pharmaceuticals

Novo Nordisk

Integrative Research Laboratories (IRLAB)

Lundbeck

US WorldMeds

Zambon

Eisai

Meiji Seika

Addex Therapeutics

Sanofi

Neurocrine Biosciences

Ono Pharmaceuticals

Otsuka Pharmaceutical

Takeda

Bial

Newron

Kyowa Hakko Kirin

Genzyme

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Parkinson’s Disease: Executive Summary

2.1 Parkinson’s Market Forecast to Reach $8.8B by 2026

2.2 New Players Expected to Establish Themselves in the Forecast Period as Late-Stage Pipeline Assets Launched

2.3 Disease-Modifying Agents and Late-Stage Complications the Largest Unmet Needs in the PD Market

2.4 Treatments for Late-Stage Complications, Including Dyskinesia and Psychosis, Provide Companies with European and Japanese Opportunity

2.5 Biologics and Reformulations Expected to Drive Growth Pipeline

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology

4.1.1 Overview

4.1.2 Aging

4.1.3 Environmental Factors

4.1.4 Genetic Factors

4.2 Pathophysiology

4.2.1 Overview

4.2.2 Mechanisms of Cell Death

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 US

5.3.2 5EU

5.3.3 Japan

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Sources Not Used

5.4.3 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for PD (2016–2026)

5.5.1 Diagnosed Prevalent Cases of PD

5.5.2 Age-Specific Diagnosed Prevalent Cases of PD

5.5.3 Sex-Specific Diagnosed Prevalent Cases of PD

5.5.4 Diagnosed Prevalent Cases of PD by Clinical Staging

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.4 Japan

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Treatment of Motor Complications – Dyskinesia and OFF Episodes

8.3 Treatment of Non-motor Complications and Dementia

8.4 Neuroprotective/Disease-Modifying Agents

8.5 Improved Drug Formulations

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 AbbVie

10.4 Roche

10.5 Orion Pharma

10.6 Impax Pharmaceuticals

10.7 Acorda Therapeutics

10.8 Adamas Pharmaceuticals

10.9 UCB

10.10 Kyowa Hakko Kirin

10.11 Other Players

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs [and Payers] Interviewed for This Report

12.4.1 KOLs

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of Tables

Table 1: Parkinson’s Disease: Key Metrics in the 7MM

Table 2: Risk Factors and Comorbidities for PD

Table 3: 7MM, Diagnosed Prevalent Cases of PD By Clinical Staging, Both Sexes, Ages ≥18 Years, N, 2016

Table 4: Treatment Guidelines for PD

Table 5: Country Profile – US

Table 6: Country Profile – 5EU

Table 7: Country Profile – Japan

Table 8: Leading Treatments for Parkinson’s Disease, 2016

Table 9: Comparison of Therapeutic Classes in Development for Parkinson’s Disease, 2016–2026

Table 10: AbbVie’s Disease Portfolio Assessment, 2018

Table 11: Roche’s Disease Portfolio Assessment, 2018

Table 12: Orion Pharma’s Disease Portfolio Assessment, 2018

Table 13: Impax Pharmaceuticals’ Disease Portfolio Assessment, 2018

Table 14: Acorda Therapeutics’ Disease Portfolio Assessment, 2018

Table 15: Adamas Pharmaceuticals’ Disease Portfolio Assessment, 2018

Table 16: UCB’s Disease Portfolio Assessment, 2018

Table 17: Kyowa Hakko Kirin’s Disease Portfolio Assessment, 2018

Table 18: Parkinson’s Disease Market – Global Drivers and Barriers, 2016–2026

Table 19: Key Events Impacting Sales for Parkinson’s Disease in the US, 2016–2026

Table 20: Parkinson’s Disease Market – Drivers and Barriers in the US, 2016–2026

Table 21: Key Events Impacting Sales for Parkinson’s Disease in the 5EU, 2016–2026

Table 22: Parkinson’s Disease Market – Drivers and Barriers in the 5EU, 2016–2026

Table 23: Key Events Impacting Sales for Parkinson’s Disease in Japan, 2016–2026

Table 24: Parkinson’s Disease Market – Global Drivers and Barriers in Japan, 2016–2026

Table 25: Key Projected Launch Dates for Parkinson’s disease

Table 26: Key Historical and Projected Patent Expiry Dates for Parkinson’s Disease

Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for Parkinson’s Disease in 2016 and 2026

Figure 2: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period

Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of PD, Ages ≥18 Years, 2016

Figure 5: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of PD, 2016–2026

Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of PD Clinical Staging, 2016–2026

Figure 7: Diagnosed Prevalent Cases of PD, 7MM, Both Sexes, ≥18 Years, N, 2016

Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages ≥18 Years, N, 2016

Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages ≥18 Years, N, 2016

Figure 10: Treatment Algorithm for Parkinson’s Patients

Figure 11: Unmet Needs and Opportunities in Parkinson’s Disease

Figure 12: Pharmacokinetics of Levodopa

Figure 13: Overview of the Development Pipeline in Parkinson’s Disease

Figure 14: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PD in the 7MM During the Forecast Period

Figure 15: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period

Figure 16: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period

Figure 17: Global (7MM) Sales Forecast by Country for Parkinson’s Disease in 2016 and 2026

Figure 18: Sales Forecast by Class for Parkinson’s Disease in the US in 2016 and 2026

Figure 19: Country Breakdown for Parkinson’s Disease Sales in the 5EU in 2016 and 2026

Figure 20: Sales Forecast by Class for Parkinson’s Disease in Japan in 2016 and 2026

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports